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The [123I]ioflupane—a dopamine transporter radioligand—SPECT (DaT-SPECT) has proven
to be useful in the differential diagnosis of tremor. Here, we investigate the diagnoses
behind patients with hard-to-classify tremor and normal DaT-SPECT. Therefore, 30 patients
with tremor and normal DaT-SPECT were followed up for 2 years. In 18 cases we were able
to make a diagnosis. The residual 12 patients underwent a second DaT-SPECT, were then
followed for additional 12 months and thereafter the diagnosis was reconsidered again.
The final diagnoses included cases of essential tremor, dystonic tremor, multisystem
atrophy, vascular parkinsonism, progressive supranuclear palsy, corticobasal degeneration,
fragile X–associated tremor ataxia syndrome, psychogenic parkinsonism, iatrogenic
parkinsonism and Parkinson’s disease. However, for 6 patients the diagnosis remained
uncertain. Larger series are needed to better establish the relative frequency of the
different conditions behind these cases.
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INTRODUCTION
Tremor is an involuntary, rhythmic, oscillatory movement of a
body part. It is the most common movement disorder encoun-
tered in clinical practice. There is no diagnostic standard to
distinguish among common types of tremor, which can make
the evaluation challenging. History and physical examination can
provide a great deal of certainty in diagnosis. However, some cases
showing more than one type of tremor or associating other signs
and symptoms are specially difficult. Establishing the underlying
cause is important because prognosis and specific treatment plans
vary considerably.
PD is a common neurodegenerative disorder characterized by
progressive degeneration of dopaminergic neurons in the sub-
stantia nigra, with loss of their nerve terminals in the basal
ganglia structures, especially in the striatum. The dopaminergic
system is the most studied neurochemical system in patients with
PD because damage to nigrostriatal neurons is the most impor-
tant component in the pathophysiology of PD. Clinically it is
characterized by the so called “parkinsonian syndrome,” consist-
ing of extrapiramidal signs, including bradykinesia and at least
one of the following: muscular rigidity, 4–6Hz rest tremor and
postural instability not caused by primary visual, vestibular, cere-
bellar, or proprioceptive dysfunction. More than 70 percent of
patients with Parkinson disease have tremor as the presenting fea-
ture. The classic parkinsonian tremor begins as a low-frequency,
pill-rolling motion of the fingers, progressing to forearm prona-
tion/supination and elbow flexion/extension. It is typically asym-
metric, occurs at rest, and becomes less prominent with voluntary
movement. Although rest tremor is one of the diagnostic crite-
ria for Parkinson disease, most patients exhibit a combination
of action and rest tremors (Rodriguez-Oroz et al., 2009). The
term “parkinsonisms” refers to a group of neurological disor-
ders characterized by a parkinsonian syndrome. In many cases,
the differential diagnosis between Parkinson disease and other
neurodegenerative parkinsonisms, or other conditions such as
essential tremor, psycogenic, or drug-induced parkinsonism is
sometimes difficult. This requires an experienced clinician and
time to establish the pattern of progression and response to
treatment.
Currently, the diagnosis of tremor remains primarily clinical,
but complementary tests may be useful to support the diag-
nostic process for particularly difficult cases, specially in those
where tremor associates with parkinsonian syndrome. Structural
imaging, such as computed tomography or magnetic resonance
imaging (MRI), is of limited value for differentiating parkinso-
nian syndromes since structural changes are often only evident by
the time the disease is far advanced. CT and MRI neuroimaging
do play an important role in the diagnosis of patients with vas-
cular parkinsonism. Radiotracer neuroimaging techniques allow
to study the integrity of the dopaminergic nigrostriatal system
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and are therefore a valuable tool to diagnose neurodegenerative
parkinsonisms (Lorenzo Bosquet et al., 2004; Tolosa et al., 2007).
Positron emission tomography techniques demonstrate the dis-
ruption of selective patterns of regional cerebral metabolism and
neurotransmitter systems associated with subcortical degener-
ations, such as Parkinson’s disease, striatonigral degeneration,
progressive supranuclear palsy, and corticobasal degeneration
(Antonini and Isaias, 2009; Huang et al., 2013). In addition, it
allows to determine, where underlying Parkinson’s disease may be
suspected and whether nigral dysfunction is present in patients
with isolated tremor or drug-associated rigidity. However, PET
scan is an expensive technique that is not available in most clinical
centers. A DaT-SPECT (Dopamine Transporter -DaT- single-
photon emission computed tomography), is a less expensive and
more widely available technique compared to PET and has already
been incorporated into clinical practice. The active ingredient
of [123I]FP-CIT SPECT is a cocaine analog, 123I-labeled N-
u-fluoropropyl 2b-carbomethoxy-3b-(4-iodophenyl) nortropane
([123I]ioflupane). It binds with high affinity to striatal presy-
naptic DAT in animals and in humans and helps visualize these
neurons with SPECT brain imaging. [123I]FP-CIT SPECT has
the advantage of faster kinetics, which allows imaging 3–6 h after
injection. DAT is located on the plasma membrane of nerve ter-
minals in a small number of neurons in the brain, especially in
the striatum and nucleus accumbens, and in the globus pallidus,
cingulate cortex, olfactory tubercle, amygdala, and midbrain.
DAT regulates the dopamine concentration in the synaptic cleft
through reuptake of dopamine into presynaptic neurons and thus
plays a central role in the buffering of the released dopamine
(Surasi et al., 2013).
The Food and Drug Administration (FDA) has recently
approved the use of DaT-SPECT “to assist in the evalua-
tion of adult patients with suspected parkinsonian syndromes”
(Figure 1). Paradoxically, however, adequate neuropathologic
validation of Parkinson’s disease diagnosis based on DaT-SPECT
findings is still lacking and the value of DaT-SPECT for clini-
cal decision-making remains unclear. Generally, the clinical based
diagnostic accuracy of Parkinson’s disease is mathematically iden-
tical to the diagnostic accuracy of DaT-SPECT imaging (6).
In terms of differential diagnoses, DaT-SPECT imaging can-
not distinguish reliably between Parkinson’s disease and other
degenerative parkinsonisms, such as multiple system atrophy or
progressive supranuclear palsy, whenever evaluated on a case-by-
case basis. This important point is specifically recognized in the
FDA briefing document (De La Fuente-Fernandez, 2012). Finally,
the alternative diagnoses to Parkinson’s disease when a patient
with hard-to-classify tremor shows a normal (negative) study are
not well known yet. Herein, we report a series of patients with
different types of tremor or tremor plus parkinsonism, where the
clinician decided to perform a DaT-SPECT due to diagnostic dif-
ficulties and the DaT-SPECT resulted normal. These patients were
followed up for 2 years at least, with the aim of revealing the final
diagnoses of these patients.
METHODS
Standard protocol approvals, registrations, and patient consents.
The study was approved by the Hospital Álvarez-Buylla and
informed consent was given by all family members.
FIGURE 1 | Normal and abnormal DAT-SPECTs. Normal DaT-SPECTs of a
patient with essential tremor at baseline (A) and 42 months later (B).
Normal DaT-SPECT of a patient with Parkinson’s disease at baseline (C).
However, 84 months later (D) the scan was abnormal due to a decrease in
postsynaptic uptake on the right striatum.
SUBJECTS
We screened patients with tremor, who had performed a DaT-
SPECT and resulted normal. The period of time for screening
patients was 5 years. Patients with dementia were ruled out,
though patients with mild cognitive impairment were allowed for
inclusion (Huang et al., 2013).
FOLLOW UP
Patients included were assessed every 6 months for 2 years at least.
Neurological examination was performed to all patients in all vis-
its. Other studies, including a second DaT-SPECT, were done in
some cases according to the neurologist criteria. At the end of the
follow up period we reconsidered diagnoses based on findings in
history, examination, response to treatment and complementary
studies. Cases in which we were unable to reach a final diagnosis
remained labeled as “uncertain diagnosis.”
IMAGING ACQUISITION
Following thyroid iodine uptake blocking with 500mg of potas-
sium perchlorate, patients underwent intravenous administration
of a single dose (148MBq)in of DaTSCAN (GE Healthcare).
SPECT imaging was carried out 3–6 h later with a dual-headed
gammacamera (Philips Healthcare) using LEHR collimators.
Data were acquired in a 128 × 128 matrix; zoom 2.19; 180◦ per
head; 20 s per view; 128 views; 158 keV; 15% window; filtered
back projection and 2-D Butterworth prefilter; power factor 8; cut
off 0.6.
DATA ANALYSIS
DaTa analysis was acquired visually and semi-quantitatively with
Xeleris 2.0 software (GE Healthcare). In order to analyze the
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dopaminergic deficit, two different methods were performed:
visual interpretation and semi- quantification with classical man-
ual ROIs (Region of Interest) method. For visual interpretation,
a nuclear medicine physician examined the hardcopy images and
classified the SPECT images into two different patterns: normal,
showing a symmetrical uptake bilaterally in putamen and caudate
nuclei; and abnormal, with different levels of uptake reduction
in one or both caudate and/or putamina. The semi- quantitative
evaluation method allows to calculate binding ratios by com-
paring activity in striatum with activity in an area of low DaT
concentration (usually the occipital area). Three consecutive slices
with the highest striatal image count were selected and summed
up to a single slice. The ratio of specific to non-specific binding
was calculated by standardized two dimensional ROIs, derived
from an anatomical brain atlas, which were placed bilaterally
over the striatum with subregions for caudate and putamen. A
ROI over the occipital cortex was used as reference region to
assess non-specific binding. Specific FP-CIT tracer uptake was
calculated for caudate and putamen using the formula: [Striatal
binding ratio = mean counts of striatal ROI-mean counts of
occipital ROI/ mean counts of occipital ROI].
RESULTS
SAMPLE DESCRIPTION
We screened 34 patients with tremor who had underwent
a DaTSPECT due to diagnostic difficulties and the result of
DaTSPECT was negative (normal). Four of the patients screened
were ruled out for suffering from dementia. The demographic
and main clinical features of the patients included are summa-
rized in Table 1.
DIAGNOSES AND FOLLOW-UP
After a follow up period (24 months) the diagnoses of all cases
were reconsidered and recorded (Figure 2). The main clinical
features allowing us to reach the diagnoses are included under
Table 2. Diagnoses included cases of essential tremor (6 cases),
dystonic tremor (2 cases), multisystem atrophy (2 cases), vascular
parkinsonism (2 cases), Parkinson’s disease (1 case), progres-
sive supranuclear palsy (1 case), corticobasal degeneration (1
case), Fragile X–associated tremor ataxia syndrome (1 case), psy-
chogenic parkinsonism (1 case), and iatrogenic parkinsonism
(1 case) (see Table 3). In twelve cases we were unable to reach
a diagnosis. These patients were labeled as “uncertain diagno-
sis.” They underwent a second DaT-SPECT and were followed
for 12 months more, with the following results: in 4 patients
the second DaT-SPECT resulted abnormal and they were finally
Table 1 | Demographics and clinical features of the patients included
in the study.
Mean age 67 years (57–79)
Gender distribution 17 males 13 females
Mean age at onset 61 years (52–74)
Evolution time at inclusion 35 months (8–58)
Mean MMSE 26 (20–30)
Mean UPDRS 24 (12–36)
Mean L-DOPA dose 564mg (0–1200)
diagnosed with Parkinson’s disease (see Discussion for details);
in 8 patients the second DaT-SPECT resulted normal again—of
those 2 were finally diagnosed with dystonic tremor, whereas 6
remained undiagnosed and labeled as “uncertain diagnosis.”
Thus, the final diagnoses included cases of essential tremor (6
cases), Parkinson’s disease (5 cases), dystonic tremor (4 cases),
multisystem atrophy (2 cases), vascular parkinsonism (2 cases),
progressive supranuclear palsy (1 case), corticobasal degeneration
(1 case), Fragile X–associated tremor ataxia syndrome (1 case),
psychogenic parkinsonism (1 case), and iatrogenic parkinsonism
(1 case) (Table 3 and Figure 3).
DISCUSSION
The acronym SWEDDs (scans without evidence of dopaminer-
gic deficits) (Schneider et al., 2007), relatively recent in usage,
arose from the clinical trial literature for Parkinson’s disease, in
which patients were imaged with 18F-dopa PET or DaT-SPECT
in order to monitor disease progression, revealing that a substan-
tial proportion of clinically diagnosed cases of Parkinson’s disease
had normal SCANS (4–15%) and were therefore designated as
SWEDDs (Schneider et al., 2007; Bajaj et al., 2012). Thus, the
term SWEDDs can be leveled at any patient diagnosed at first with
Parkinson’s disease but subsequent functional imaging assess-
ments do not confirm the presynaptic, dopaminergic deficiency
origin.
From the semiological point of view, SWEDDs phenotypes
vary in much the same way as Parkinson’s disease pheno-
types do. There are two broad Parkinson’s disease phenotypes,
akinetic-rigid (also known as postural instability gait disorder
variant -PIGD) and tremor dominant (also known as tremulous
Parkinson’s disease). In the same way, SWEDDs patients can be
subdivided into tremor dominant and non-tremor dominant (or
tremor absent) subtypes. With this and the knowledge of the clin-
ical picture of other parkinsonisms in mind, the clinician in front
of a patient with SWEDDs can usually reach a diagnosis, in many
cases after a follow up period (De La Fuente-Fernandez, 2012).
In the following, we discuss in detail the different diagnoses we
found and describe the main clues to consider each one.
FIGURE 2 | Study design.
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Table 2 | Main clinical features of every subject included in the study listed by final diagnoses.
Final diagnos Tremor Rigidity Brady kinesia Postural stability Gait Others ResponL-dopa
ET1 Sym, P,A,V,C + − + + MCI NT
ET2 Sym, P,A,V,C − − + + NT
ET3 Asym, P,A − − + + −
ET4 Sym, P,A,V,C + − + + MCI NT
ET5 Sym, P,A − − + + −
ET6 Sym, P,A,C − − + + NT
PD1 Asym, P, R +, F + + − ++
PD2 Asym, R +, F + + + MCI ++
PD3 Asym, R +, F + − + ++
PD4 Asym, P, R +, F + − + MCI ++
PD5 Asym, R + + − + ++
DT1 Asym, R − − + + Dystonia −
DT2 Asym, R, J + − − − Dystonia −
DT3 Asym, R − − + + Dystonia −
DT4 Asym, R − − + + Dystonia −
MSA1 Sym, P, J + + − − UMS AD AC +
MSA2 Asym, P, A. R, J +, F + − − MCI UMS Stridor +
VP1 Sym, P,A + + + + UMS +
VP2 Sym, P,A + − + + UMS −
PSP1 Sym, P +, F + − − SGP AS −
CBD1 Asym, P, R + + − − MCI MC Apraxia −
FXTAS Sym, P,A,R,V,C + − − − Ataxia −
Psycho1 Sym, P,A, R − − − − Incons Distrac NT
Iatro1 Sym, P,A, R + + + + Dyskinesia +
?1 Asym, P, R + − + + MCI −
?2 Asym, P, R − + − − MCI UMS −
?3 Asym, P, R − + + + MCI MC Apraxia −
?4 Asym, P, R +, F − − − Dystonia −
?5 Sym, P,A,R,V,C − − − − MCI Ataxia +
?6 Asym, P, R − − + + MCI Apraxia −
Acronims and clues by columns: Final diagnoses: ET, Essential Tremor; PD, Parkinson’s disease; DT, Dystonic tremor; MSA, Multiple system Atrophy; VP, Vascular
parkinsonism; PSP, Progressive supranuclear palsy; CBD, Corticobasal degeneration; FXTAS, Fragile X–associated tremor ataxia syndrome; Psychog, Psychogenic
parkinsonism; Iatro, Iatrogenic parkinsonism; ?, unclear diagnosis. Tremor: − = Absent Sym, Symmetrical in limbs; Asym, Asymmetrical in limbs; R, Rest tremor; P,
Postural tremor; A, Action tremor; J, Jerky tremor; V, Vocal tremor; C, Cephalic tremor. Rigidity: + = present, − = absent, F, Froment sign positive; Bradykinesia: + =
present, − = absent, Postural stability: + = normal, − = abnormal, Gait: + = normal, − = abnormal. Others: UMS, upper motor neuron signs; MCI, Mild cognitive
imparirment; AD, Autonomic dysfunction; AC, Antecollis; SGP, Supranuclear gaze palsy; AS, Applause sign; MC, Myoclonus; Incons, inconsistent exploratory signs;
Distract, Distractability. Response to L-Dopa: ++ = very good, + = good, − = poor or negative, NT, not tested.
Although abnormal in most patients with Parkinson’s disease,
a normal DaT-SPECT is not capable to totally exclude the
disease (Vlaar et al., 2007, 2008; Serrano Vicente et al., 2009). A
meta-analysis was conducted by Vlaar and colleagues to review
the diagnostic accuracy of SPECT to differentiate between early
phase of PD and normalcy. All the 6 cross-sectional studies (using
presynaptic tracers) with patients with known PD in an early
stage (Hoehn and Yahr score of 2 or lesser) had a specificity of
100% and the sensitivity varied from 8% to 100% (Vlaar et al.,
2007, 2008). A possible explanation for the low sensitivity found
in some studies is that DaT-SPECT can be normal in the very
initial stages of the disease. Indeed we diagnosed 1 case with
Parkinson’s disease in spite of having a normal DaT-SPECT.
At least two studies found that in cases that undergo a second
DaT-SPECT the accordance of the result with the final clinical
diagnosis was higher in the second DaT-SPECT than in the first
one (Vlaar et al., 2007, 2008; Serrano Vicente et al., 2009), thus
suggesting that the result of the first DaT-SPECT of patients
with Parkinson’s disease can be negative if performed too early
and become positive later on. In our study 4 out of 12, in which
a second DaT-SPECT was performed, resulted abnormal. All
these patients responded well to L-DOPA or agonists and had a
typical parkinsonian syndrome, therefore they were diagnosed
with Parkinson’s disease eventually. Another explanation for
the relatively high number of false-negative Parkinson’s disease
patients is the quantitative analysis of the SPECT scans. When
recalculating the accuracy of DaT-SPECTs to differentiate
patients with idiopathic Parkinson’s disease from those with
essential tremor using visual qualitative judgment instead of
quantitative analysis studies report the sensitivity increased from
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80% to 94%, negative predictive value from 48 to 71%, specificity
and positive predictive value stayed unchanged (Vlaar et al.,
2008; Marshall et al., 2009). However, the rule is that the vast
majority of patients with Parkinson’s disease have an abnormal
DaT-SPECT and a normal DaT-SPECT should always make us
reconsider the diagnosis of Parkinsons, even in early stages.
Table 3 | Cases diagnosed after the first and second DaT-SPECTs and
follow-up periods.
Diagnoses DaT-SPECT (prefollow-up) Total
(final
diagnoses)After first After second
follow-up follow-up
period (n = 30) period (12/30)
Normal Normal Abnormal
Essential tremor 6 − − 6
Parkinson’s
disease
1 − 4 5
Dystonic tremor 2 2 − 4
Multisystem
atrophy
2 − − 2
Vascular
parkinsonism




1 − − 1
Corticobasal
Degeneration





1 − − 1
Psychogenic
parkinsonism
1 − − 1
Iatrogenic
parkinsonism
1 − − 1
Uncertain 12 6 − 6
Essential tremor may be confused with parkinsonism for sev-
eral reasons. Firstly, although essential tremor is characterized
by a tremor that is exacerbated by posture-holding and action,
these patients may also have a tremor at rest (Cohen et al., 2003;
Rajput et al., 2004), whereas parkinsonian patients may also have
a postural tremor. Secondly, even though the other cardinal fea-
tures may be discriminating, some essential tremor patients do
have mild rigidity (Rajput et al., 2004), whereas some patients
with early Parkinson’s disease may present with an isolated rest
or postural tremor without any other features of parkinsonism.
Some patients with a late onset, markedly asymmetrical postu-
ral tremor that was diagnosed initially as essential tremor but
who went on after many years to develop typical Parkinson’s dis-
ease (Chaudhuri et al., 2005). When in doubt, follow up and
response to treatments are crucial as those with PDwill eventually
progress to develop clear parkinsonian features and respond to
dopaminergic therapies. Multiple studies report that DaT-SPECT
can distinguish parkinsonian syndrome from essential tremor
(Asenbaum et al., 1998; Tolosa et al., 2007; Antonini and Isaias,
2009; Surasi et al., 2013). In fact, essential tremor was usually
chosen as the comparator disorder for many studies since it was
thought to have normal striatal DaT. However, DaT-SPECT in
essential tremor is not always normal, or at least not as normal as
in controls; further suggesting a potential link of some essential
tremor cases with Parkinson’s disease (Isaias et al., 2008; Antonini
and Isaias, 2009; Gerasimou et al., 2012; Labiano-Fontcuberta
and Benito-Leon, 2012).We found essential tremor to be themost
common cause of tremor with normal DaT-SPECT (6/30 cases).
Primary adult-onset dystonia can present with an asymmet-
ric resting arm tremor, with impaired arm swing and sometimes
also facial hypomimia or a jaw tremor, but without evidence
of true akinesia (Schneider et al., 2007). Tremor is a relatively
common feature occurring in about 17% of patients with pri-
mary late-onset dystonia (Defazio et al., 2013). The association
between tremor and dystonia spread suggests that this form
of tremor may be a dystonic manifestation. Tremor may be
classified either as dystonic tremor or tremor associated with
dystonia (TAWD) according to the Movement Disorder Society
FIGURE 3 | Pie graph showing the distribution of final diagnoses and relative frequencies.
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Consensus Statement (Deuschl et al., 1998). Similarities in phe-
notypic features of dystonic tremor and TAWD predominate over
differences, suggesting that the two forms of tremor may be
manifestations of the same disease (Defazio et al., 2013; Tinazzi
et al., 2013). Differences in gender, body distribution and tem-
poral thresholds of tremor between patients with dystonia and
tremor and those of patients with essential tremor also indi-
cate that tremor in dystonia and essential tremor are different
entities (Defazio et al., 2013; Tinazzi et al., 2013). Patients with
primary adult-onset dystonia show normal DaT-SPECT studies
(Schneider et al., 2007). Neurophysiological studies also show that
the pattern of plasticity of sensorimotor circuits in patients with
tremor dominant SWEDDs resembles the pattern seen in dysto-
nia patients and differs from the pattern found in patients with
Parkinson’s disease (Schwingenschuh et al., 2010), thus suggest-
ing that many patients with tremulous SWEDDs may have in
fact dystonia (Bajaj et al., 2010). In our series 4/30 patients were
diagnosed with dystonic tremor. All these patients had a tremoric
parkinsonian syndrome with a clear dystonic component in their
tremor. Some dystonic signs may also be present in Parkinson’s
disease, though these are usually mild. In addition, patients with
dystonic tremor do not respond to L-DOPA or dopaminergic
agonists (Bajaj et al., 2010).
As indicated by its name, progressive supranuclear palsy (PSP)
is characterized by a supranuclear gaze palsy with hypometric or
slow saccades, particularly on downgaze (Stamelou et al., 2010).
However, in the early stages, these abnormalities are often absent
and occasionally they do not develop at all (Nath et al., 2003;
Williams et al., 2005). DaT-SPECT studies are usually abnormal
as in Parkinson’s disease. In our series only 1 case was diagnosed
with PSP. This case progressed rapidly to the development of
the typical picture of PSP with cognitive dysfunction and poor
response to L-DOPA.
Fragile X–associated tremor ataxia syndrome (FXTAS) defined
by fragile X mental retardation 1 (FMR1) premutation, cerebellar
ataxia, intentional tremor, middle cerebellar peduncle hyperin-
tensities in MRI and peripheral neuropathy (Jacquemont et al.,
2003; Apartis et al., 2012). About a half of patients with FTAX
have abnormal DaT-SPECT (Apartis et al., 2012). One case in
our series was diagnosed with FXTAS during follow up based
on the genetic study (90–100 CGG Repeats in Gen FMR1). This
case was a woman who had been followed in our center for years
due to a tremoric parkinsonian syndrome. She was put on sev-
eral antitremoric treatments, but her tremor only responded to
Primidone.
Most cases of symptomatic parkinsonism are vascular parkin-
sonism. Basal ganglia infarct is a relatively uncommon cause
of parkinsonism, but diffuse cerebrovascular disease is much
more frequent (Sibon and Tison, 2004; Thanvi et al., 2005).
Qualitatively DaT-SPECT images are normal in about a third of
patients with vascular parkinsonism. The use of different visual
score patterns showed higher ability to differentiate vascular
parkinsonism from Parkinson’s disease. Semi-quantitative anal-
ysis showed significantly higher uptake in the striatum, caudate
and putamen in vascular parkinsonism. Among patients with
vascular parkinsonism, falls were the only clinical feature that
demonstrated a correlation with the SPECT visual pattern
(Benitez-Rivero et al., 2013). In spite of the fact that most
cases of symptomatic parkinsonism are vascular parkinsonism
we only had 2 cases in our series. This is probably due to
the fact that in our center all patients with parkinsonian syn-
drome undergo neuroimaging and those with high vascular
load are not asked to perform a DaT-SPECT, for this reason
they were not included in this study. However, two patients
with vascular risk factors, low vascular load and a normal
DaT-SPECT at screening were finally diagnosed with vascular
parkinsonism due to fast progression to the typical vascular
parkinsonian syndrome and increase in the vascular load in new
neuroimaging studies. This suggests that early parkinsonian syn-
drome may be due to vascular lesions in spite of low vascular
load in initial neuroimaging studies, and both clinical and neu-
roimaging follow up are needed when vascular risk factors are
present.
Many drugs can cause parkinsonism, most commonly antipsy-
chotics and antiemetics; and more rarely others such as methyl-
dopa, calcium antagonists, and sodium valproate among many
others. Therefore, before making the diagnosis of Parkinson’s
disease, it is important to check the patient’s medication (both
current and previous). If the patient is on a relevant drug,
it should be stopped if possible, and the patient followed up.
Drug induced parkinsonism can take several months to resolve
after the drug is discontinued. And even if the symptoms do
improve, follow up has shown that a few of these patients will
later develop Parkinson’s disease, suggesting that the drug had
unmasked subclinical Parkinson’s disease (Chabolla et al., 1998;
Lopez-Sendon et al., 2013). If the drug cannot be stopped, it
can be very difficult to distinguish drug induced parkinson-
ism from idiopathic PD. In this situation, functional imaging
with a dopamine transporter ligand may be useful, because
patients with pure drug induced parkinsonism have normal scans
(Booij et al., 2001; Marshall et al., 2009; Tinazzi et al., 2012).
However, contrary to what one would expect, several studies have
encountered abnormal DaT-SPECT findings in a surprisingly
high number of patients clinically diagnosed as having drug-
induced parkinsonism (Sibon and Tison, 2004; Thanvi et al.,
2005; Lorberboym et al., 2006). Drug-induced downregulation
of DaT expression is certainly a possibility. D2-receptor block-
ade may coexist with a dopamine nigrostriatal terminal defect,
as assessed by DaT-SPECT abnormalities, in a relevant pro-
portion of patients with drug induced parkinsonism (Schneider
et al., 2007). In other words, DaT-SPECT imaging does not
predict whether a given neuroleptic-treated patient will develop
parkinsonism or not.
Functional or “psychogenic” parkinsonism is well recognized
but relatively rare. If there is doubt about this diagnosis, careful
follow up and functional imaging may resolve the uncertainty
as studies are usually normal. However, contrary to what one
would expect, several authors reported abnormal DaT-SPECT
findings in a surprisingly high number of patients clinically diag-
nosed as having psychogenic (Lang et al., 1995; Hallett, 2011;
Lang and Voon, 2011). It remains unknown whether these imag-
ing changes are functional or structural in nature. In our study
only 1 patient was diagnosed with psychogenic parkinsonian
syndrome.
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Multiple system atrophy (MSA), also known as striatonigral
degeneration or one variant as Shy-Drager syndrome is character-
ized by a variable combination of parkinsonism, cerebellar ataxia
and/or autonomic dysfunction (Ubhi et al., 2011; Ahmed et al.,
2012). In our study 2 patients were diagnosed with MSA. They
progressed quickly although responded well to L-DOPA initially.
Corticobasal degeneration is characterized by a combination
of atypical parkinsonism and higher cortical dysfunction, even
when one of these often dominates the clinical picture. Decreased
presynaptic dopamine transporter binding have been found in
most CBD patients (Hossain et al., 2003; Klaffke et al., 2006).
Other study in a large CBS population found DaT-SPECT to
be normal in about 10% of cases despite prominent bilateral
extrapyramidal signs. In these cases, clinical and neuropsycho-
logical features were not distinct from those with evidence of
SNc neuronal loss. The lack of any correlation between presynap-
tic nigrostriatal dysfunction and disease duration might suggest
an unpredictable and possibly delayed SNc degeneration in CBD
and further supports the hypothesis of a variable contribution
of supranigral pathology to its motor phenotype (Cilia et al.,
2011). In our series only 1 patient was diagnosed with corti-
cobasal degeneration. She progressed toward dementia and severe
dyspraxia quickly.
Repeating DaT-SPECT studies over time can reduce the diag-
nostic uncertainty that is present even after a prolonged period of
observation (Vlaar et al., 2007; Antonini and Isaias, 2009). Of the
12 cases in which we repeated a second SPECT, the result changed
to abnormal in 4. These patients were diagnosed with Parkinson’s
disease. However, after a second DaT-SPECT some patients still
remain undiagnosed and other studies (such as PET studies) or
even longer times of follow up are needed to move these patients
in the diagnostic classification from “SWEDDs” to true nosologi-
cal entities. As we have seen here, it seems clear that some patients
with SWEDDs (those with predominant tremor subtype) have in
fact dystonia, whereas others have other entities which are also
well-known but may need some reassessment and follow-up to
reach the diagnosis. In addition, it is conceivable that a number
of patients might suffer from a disorder that has not yet been
described.
Some patients with clinically uncertain parkinsonian syn-
drome exhibit outstanding frontal dysfunction. It is well known
that cognitive impairment in early Parkinson’s disease and
other synucleinpathies (Parkinson-plus syndromes) are accom-
panied by reductions in activity in frontostriatal neural circuitry
(Zgaljardic et al., 2003, 2004). These patients usually have an
abnormal DaT-SPECT as the damage in frontostriatal neural
circuitry occurs from down (basal ganglia) to up (frontal cor-
tex) (Zgaljardic and Feigin, 2004). We speculate that some of
the patients with clinically uncertain parkinsonian syndrome and
normal DaT-SPECT studies may have a frontal neurodegener-
ative process involving fronto-subcortical circuits from top to
bottom, that remains to be described. We have the hypothesis
that some kind of neurodegenerative disorder affecting motor
frontosubcortical circuits primary may exist, where parkinson-
ism is remarkable and frequently the first manifestation besides
a disejecutive syndrome, although these patients do not usu-
ally meet the full criteria of frontotemporal lobe dementia.
Functional neuroimaging and eventually neuropathological stud-
ies should be done in a cohort of these patients to confirm
this extreme.
In conclusion, DaT-SPECT can be useful in the process of
diagnosing tremor but it should not be relied on as a substi-
tute for a careful, experienced clinical assessment and follow
up. It is important to be well aware of the clinical clues to dif-
ferentiate between these disorders. There is a list of alternative
diagnoses to consider when a patient with tremor presents with
normal DaT-SPECT, including disorders where it is expected
to be normal, such essential tremor, dystonic tremor, vascu-
lar parkinsonism, drug induced parkinsonism among others,
although the diagnosis of presynaptic parkinsonisms, including
Parkinson’s disease, is possible too. Repeating DaT-SPECTs over
time may be useful in some circumstances since it can reduce
the remaining diagnostic uncertainty that is present even after
a prolonged period of observation. Especially, clinicians should
consider repeating the DaT-SPECT when the clinical picture is
consistent with typical early Parkinson’s disease. However, after
a second DaT-SPECT some patients still remain undiagnosed
and other studies or even longer times of follow up are needed
to move the diagnose of these patients from “SWEDDs” to true
nosological entities.
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